ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
2,1,Alpha 1 foetoprotein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
4,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
5,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
5,2,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
6,1,Porphyria,Inborn errors of porphyrin metabolism,Metabolic and nutritional disorders congenital,Cong,N
7,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
7,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
9,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
9,2,Gastric cancer,Gastric neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
9,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
10,1,Craniopharyngioma,Nervous system neoplasms benign NEC,Nervous system neoplasms benign,Neopl,N
10,2,Diabetes insipidus,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
10,3,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
10,4,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
11,1,Neurological symptom,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
12,1,Drowning,Death and sudden death,Fatal outcomes,Genrl,Y
13,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
13,2,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
13,3,Succinylacetone increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
13,4,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
14,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
14,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
14,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
15,1,Executive dysfunction,Cognitive and attention disorders and disturbances NEC,Cognitive and attention disorders and disturbances,Psych,N
15,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
15,3,Motor dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
15,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
16,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
16,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
17,1,Megacolon,Non-mechanical ileus,Gastrointestinal motility and defaecation conditions,Gastr,Y
18,1,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,Y
18,2,Methaemoglobinaemia,Haematological disorders,Haematological disorders NEC,Blood,N
19,1,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
20,1,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
21,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
21,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
21,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
21,4,Porphyria,Inborn errors of porphyrin metabolism,Metabolic and nutritional disorders congenital,Cong,N
21,5,Succinylacetone increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
21,6,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
22,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
22,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
22,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
22,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
22,5,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
22,6,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
22,7,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
22,8,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
22,9,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
22,10,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
22,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
23,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
23,2,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
23,3,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
23,4,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
23,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
23,6,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
23,7,Hypovolaemia,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
23,8,Neutrophilia,Leukocytoses NEC,White blood cell disorders,Blood,N
23,9,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
23,10,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
24,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
24,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
24,4,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
24,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
24,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
24,7,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,8,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
25,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
25,2,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
25,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
25,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
25,5,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
26,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
26,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
26,3,Faecaloma,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
26,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
26,5,Hypovolaemia,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
26,6,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
26,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
27,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
27,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
27,3,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
27,4,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
27,5,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
27,6,Myopathy,Myopathies,Muscle disorders,Musc,N
27,7,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
27,8,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
27,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
27,10,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
28,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
28,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
29,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
29,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
29,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
30,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
30,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
30,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
31,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
31,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
32,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
32,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
32,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
33,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
33,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
33,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
34,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
34,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
34,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
35,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
35,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
35,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
36,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
36,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
36,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
37,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
37,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
37,3,Conjunctival oedema,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
37,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
38,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
38,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
38,3,Conjunctival oedema,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
38,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
39,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
39,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
39,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
40,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
40,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
40,3,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
40,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
41,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
41,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
41,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
42,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
42,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
42,3,Conjunctival cyst,Ocular cysts and polyps,Ocular neoplasms,Eye,N
42,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
43,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
43,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
44,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
44,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
44,3,Conjunctival disorder,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
44,4,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
44,5,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
45,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
45,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
45,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
46,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
46,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
46,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
47,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
47,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
47,3,Cataract nuclear,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
47,4,Conjunctival disorder,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
47,5,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
47,6,Scleral disorder,"Scleral structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
48,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
48,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
48,3,Corneal neovascularisation,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
48,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
48,5,Scleral pigmentation,"Scleral structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
49,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
49,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
49,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
50,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
50,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
51,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
51,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
51,3,Conjunctival pigmentation,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
51,4,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
51,5,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
51,6,Scleral disorder,"Scleral structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
52,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
52,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
52,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
53,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
53,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
53,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
54,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
54,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
54,3,Nasal disorder,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
55,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
55,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
56,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
56,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
56,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
57,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
57,2,Cataract nuclear,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
57,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
58,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
58,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
58,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
59,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
59,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
59,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
60,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
60,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
60,3,Mydriasis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
61,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
61,2,Cataract cortical,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
61,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
61,4,Meibomian gland dysfunction,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
61,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
62,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
62,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
62,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
62,4,Ocular vascular disorder,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
62,5,Scleral disorder,"Scleral structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
63,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
63,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
63,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
64,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
64,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
64,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
65,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
65,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
65,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
66,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
66,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
66,3,Cataract nuclear,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
66,4,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
67,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
67,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
67,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
68,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
68,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
68,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
69,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
69,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
69,3,Lenticular opacities,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
70,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
71,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
71,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
72,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
73,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
73,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
74,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
74,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
75,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
76,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
76,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
77,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
78,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
79,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
79,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
80,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
81,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
82,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
83,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
83,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
84,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
85,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
86,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
87,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
88,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
89,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
89,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
90,1,Primary hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
90,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
90,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
90,4,Vitiligo,Hypopigmentation disorders,Pigmentation disorders,Skin,N
91,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
92,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
93,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
94,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
95,1,Vitiligo,Hypopigmentation disorders,Pigmentation disorders,Skin,N
96,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
96,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
97,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
97,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
98,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
98,2,Gastric cancer,Gastric neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
98,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
98,4,Keratopathy,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
98,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
99,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
99,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
99,3,Keratopathy,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
99,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
99,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
99,6,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
99,7,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
99,8,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
100,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
100,2,Keratopathy,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
100,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
101,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
102,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
103,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
104,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
105,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
106,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
106,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
107,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
107,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
108,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
108,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
109,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
109,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
110,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
110,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
111,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
111,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
111,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
111,4,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,Y
112,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
112,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
112,3,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
113,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
113,2,Joint injury,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
113,3,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
113,4,Tyrosinaemia,Inborn errors of amino acid metabolism,Metabolic and nutritional disorders congenital,Cong,N
113,5,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
114,1,Amino acid level increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
114,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
114,3,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
